GLOBUS MEDICAL (GMED) Stock: Buy, Sell, or Hold?
GMED - GLOBUS MEDICAL INC
$74.19
0.63 (0.86%)
▲
5d:
-5.03%
30d:
-13.4%
90d:
-7.86%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When GMED Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: GMED shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: GMED shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$129.25
Based on 6.0% avg growth
INTRINSIC VALUE TODAY
$80.26
7.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMED is currently trading at $74.19, which is considered oversold relative to its 30-day fair value range of $78.09 to $86.05. From a valuation perspective, the stock is trading at a discount (Forward PE: 13.7) compared to its historical average (17.9). Remarkably, the market is currently pricing in an annual earnings decline of 8.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMED is in a downtrend. The price is currently testing key support at $72.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GMED scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $103.23 (+39.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GMED is in a downtrend. The price is currently testing key support at $72.84. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: GMED scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $103.23 (+39.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$78.09 -
$86.05
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding GMED? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 39.1% below Wall St target ($103.23)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$78.09 -
$86.05
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$72.84
Resistance Level
$83.53
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.74
Wall Street Target
$103.23
(+39.1%)
Revenue Growth (YoY)
5.9%
Earnings Growth (YoY)
-26.2%
Profit Margin
17.0%
Valuation Discount vs History
-8.5% cheaper
PE vs Historical
13.7 vs 17.9
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.5%
(market-implied from PE analysis)
1-Year Target
$67.88
(-9%)
2-Year Target
$62.11
(-16%)
3-Year Target
$56.83
(-23%)
3-Yr Target (if PE normalizes)
(PE: 14→18)
$74.02
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 8.0%)
$136.99
(+85%)
Base:
(SPY PE: 13.7, Growth: 8.0%)
$93.34
(+26%)
Bear:
(PE: 11.7, Growth: 8.0%)
$79.34
(+7%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (19x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 19.06 | Current EPS (TTM): $3.86
Bull Case
$113.16
(+53%)
Analyst growth 39.8%, PE expands to 21.0
Base Case
$102.87
(+39%)
Market implied 39.8%, PE stable at 19.1
Bear Case
$50.02
(-33%)
Severe decline -20.0%, PE contracts to 16.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 13.7 to 17.9
Stabilization Target:
$96.63
(+30.2%)
PE Expansion Potential:
+30.2%
Share & Embed Analysis
Last updated: September 13, 2026 7:48 AM ET
Data refreshes hourly during market hours. Next update: 8:48 AM
Data refreshes hourly during market hours. Next update: 8:48 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMED showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 44 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
Advanced GMED Option Strategies
Professional options setups generated by AI based on today's GMED price and gamma walls.
